Whether you are a patient, a referring physician, a researcher, or a future resident or fellow, I would like to welcome you and thank you for your continued support. I am honored to be part of a team of faculty and staff with a rich tradition of academic and research excellence. READ THE FULL MESSAGE
Sylvester Leads Study on New Treatment Option for Brain Tumor that Relapses or Fails to Respond to Standard of Care
Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School of Medicine and published in Neuro-Oncology, the journal of the Society for Neuro-Oncology. Gliomas are...